ReviewCurrent health sciences journal
Recent Advances in the Etiology and Neural Pathways Underlying Attention-Deficit and Hyperactivity Disorder.
Review in Current health sciences journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dopamine-Derived Oxidative Stress in Attention-Deficit/Hyperactivity Disorder: A Narrative Review of Molecular Mechanisms, Neural Circuitry, and Therapeutic Implications.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of mental disorders is increasing across the European Union, with at least one in four individuals expected to experience a psychiatric condition at some point in their lifetime. Notably, men and women often present with distinct symptomatology. Among neuropsychiatric disorders, attention-deficit/hyperactivity disorder (ADHD) is the most common and functionally impairing condition in childhood, affecting approximately 5% of minors. Its persistence into adulthood is substantial, with prevalence estimates reaching up to 3% in adult populations. ADHD is characterized by dysregulated dopaminergic signaling, which disrupts reward processing and motivation. Additionally, disturbances in circadian rhythms contribute to sleep dysregulation and metabolic dysfunction, further exacerbating symptom severity. While both mechanisms have been well-documented, their interaction remains insufficiently explored, particularly regarding its implications for diagnosis and treatment optimization. Future research should systematically examine the interplay between dopaminergic and noradrenergic dysfunction and circadian disruptions in ADHD, particularly in relation to symptom expression and comorbid conditions. Experimental paradigms assessing reward processing may provide valuable insights into dopamine and norepinephrine system alterations, while chronotherapeutic interventions-such as light therapy, sleep regulation, and behavioral adjustments-hold promise as potential therapeutic strategies. By integrating perspectives from neurobiology, chronobiology, and psychopharmacology, a more refined and individualized approach to ADHD management can be developed. Advancing this understanding may not only enhance ADHD treatment strategies but also yield novel therapeutic avenues for addressing its frequently co-occurring conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.